Cost-effectiveness of HPV vaccination in the Netherlands

July 1, 2009

Even under favorable assumptions, including lifelong protection against 70% of all cervical cancers and no side effects, vaccination against the human papillomavirus (HPV) is not cost-effective in the Netherlands, according to a study published online July 1 in the Journal of the National Cancer Institute.

Researchers conducted the study because the cost effectiveness of HPV vaccination may be limited by the low number of cervical cases and deaths in the region associated with the current Dutch screening program.

In the study, Inge M.C.M. de Kok of the Department of Public Health at Erasmus MC, University Medical Center in Rotterdam, the Netherlands, and colleagues estimated the costs and effects of adding HPV vaccination to the current program (screening only) using a microsimulation screening analysis model.

They found that adding HPV vaccination was not cost-effective, even under favorable assumptions.

"To become cost-effective, the price would have to be decreased considerably, depending on the effectiveness of the vaccine," the authors write.

Source: Journal of the National Cancer Institute (news : web)

Related Stories

Recommended for you

Fighting cancer with the power of immunity

October 24, 2016

Harnessing the body's own immune system to destroy tumors is a tantalizing prospect that has yet to realize its full potential. However, a new advance from MIT may bring this strategy, known as cancer immunotherapy, closer ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.